Reactive oxygen species: Players in the cardiovascular effects of testosterone

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 310, Issue 1, 2016, Pages R1-R14

  Tostes, Rita C ^a   Carneiro, Fernando S ^a   Carvalho, Maria Helena C ^a   Reckelhoff, Jane F ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Antioxidant; Cardiovascular; Prooxidant

Indexed keywords

ANDROSTANOLONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRITE REDUCTASE [NAD(P)H]; PROSTAGLANDIN SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; TESTOSTERONE; XANTHINE OXIDASE;

ADRENAL INSUFFICIENCY; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; APPETITE DISORDER; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; ERECTILE DYSFUNCTION; HEART INFARCTION; HYPOGONADISM; HYPOPITUITARISM; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; MALE INFERTILITY; OSTEOPOROSIS; OXIDATIVE STRESS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; ADVERSE EFFECTS; AGE; ANIMAL; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MALE; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

AGE FACTORS; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS; SEX FACTORS; SIGNAL TRANSDUCTION; TESTOSTERONE;

EID: 84956941165     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00392.2014     Document Type: Review

References (207)

1. Ahlbom E, Grandison L, Bonfoco E, Zhivotovsky B, Ceccatelli S. Androgen treatment of neonatal rats decreases susceptibility of cerebellar granule neurons to oxidative stress in vitro. Eur J Neurosci 11: 1285–1291, 1999.
2. Ahlbom E, Prins GS, Ceccatelli S. Testosterone protects cerebellar granule cells from oxidative stress-induced cell death through a receptor mediated mechanism. Brain Res 892: 255–262, 2001.
3. Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, Rinaldi M, Burnett BP, Squadrito F, Bitto A. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. Br J Pharmacol 167: 95–108, 2012.
4. Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med 42: 119–134, 2012.
5. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, Wang TJ, Knapp PE, D’Agostino RB, Bhasin S, Vasan RS. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med 145: 176–184, 2006.
6. Askew EB, Gampe RT Jr, Stanley TB, Faggart JL, Wilson EM. Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem 282: 25,801–25,816, 2007.
7. Aydilek N, Aksakal M, Karakilcik AZ. Effects of testosterone and vitamin E on the antioxidant system in rabbit testis. Andrologia 36: 277–281, 2004.
8. Azevedo RB, Lacava ZG, Miyasaka CK, Chaves SB, Curi R. Regulation of antioxidant enzyme activities in male and female rat macrophages by sex steroids. Braz J Med Biol Res 34: 683–687, 2001.
9. Barp J, Araujo AS, Fernandes TR, Rigatto KV, Llesuy S, Bello-Klein A, Singal P. Myocardial antioxidant and oxidative stress changes due to sex hormones. Braz J Med Biol Res 35: 1075–1081, 2002.
10. Barrettconnor E, Khaw KT. Endogenous sex-hormones and cardiovascular- disease in men—a prospective population-based study. Circulation 78: 539–545, 1988.
11. Barton M, Prossnitz ER, Meyer MR. Testosterone and secondary hypertension: new pieces to the puzzle. Hypertension 59: 1101–1103, 2012.
12. Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab 95: 1533–1543, 2010.
13. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S. Adverse events associated with testosterone administration. N Engl J Med 363: 109–122, 2010.
14. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 5: 427–448, 2009.
15. Bekesi G, Kakucs R, Varbiro S, Racz K, Sprintz D, Feher J, Szekacs B. In vitro effects of different steroid hormones on superoxide anion production of human neutrophil granulocytes. Steroids 65: 889–894, 2000.
16. Boje A, Moesby L, Timm M, Hansen EW. Immunomodulatory effects of testosterone evaluated in all-trans retinoic acid differentiated HL-60 cells, granulocytes, and monocytes. Int Immunopharmacol 12: 573–579, 2012.
17. Booth A, Johnson DR, Granger DA. Testosterone and men’s health. J Behav Med 22: 1–19, 1999.
18. Boveris A, Cadenas E. Mitochondrial production of superoxide anions and its relationship to the antimycin insensitive respiration. FEBS Lett 54: 311–314, 1975.
19. Brandes RP, Schroder K. NOXious phosphorylation: Smooth muscle reactive oxygen species production is facilitated by direct activation of the NADPH oxidase Nox1. Circ Res 115: 898–900, 2014.
20. Brandes RP, Takac I, Schroder K. No superoxide–no stress?: Nox4, the good NADPH oxidase! Arterioscler Thromb Vasc Biol 31: 1255–1257, 2011.
21. Brinkmann AO. Molecular mechanisms of androgen action—a historical perspective. Methods Mol Biol 776: 3–24, 2011.
22. Brown-Séquard C. The effects produced on man by subcutaneous injections of a liquid obtained from the testicles of animals. Lancet 20: 105–107, 1889.
23. Callera GE, Montezano AC, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM. c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 46: 1032–1038, 2005.
24. Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, Barany P, Heimburger O, Stenvinkel P. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 26: 184–190, 2011.
25. Carter JR, Durocher JJ, Larson RA, DellaValla JP, Yang H. Sympathetic neural responses to 24-hour sleep deprivation in humans: sex differences. Am J Physiol Heart Circ Physiol 302: H1991–H1997, 2012.
26. Cauley JA, Gutai JP, Kuller LH, Dai WS. Usefulness of sex steroidhormone levels in predicting coronary-artery disease in men. Am J Cardiol 60: 771–777, 1987.
27. Chainy GB, Samantaray S, Samanta L. Testosterone-induced changes in testicular antioxidant system. Andrologia 29: 343–349, 1997.
28. Chao TC, Van Alten PJ, Walter RJ. Steroid sex hormones and macrophage function: modulation of reactive oxygen intermediates and nitrite release. Am J Reprod Immunol 32: 43–52, 1994.
29. Chaves EA, Pereira-Junior PP, Fortunato RS, Masuda MO, de Carvalho AC, de Carvalho DP, Oliveira MF, Nascimento JH. Nandrolone decanoate impairs exercise-induced cardioprotection: role of antioxidant enzymes. J Steroid Biochem Mol Biol 99: 223–230, 2006.
30. Chen YR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res 114: 524–537, 2014.
31. Cheuk BL, Leung PS, Lo AC, Wong PY. Androgen control of cyclooxygenase expression in the rat epididymis. Biol Reprod 63: 775–780, 2000.
32. Chignalia AZ, Oliveira MA, Debbas V, Dull RO, Laurindo FR, Touyz RM, Carvalho MH, Fortes ZB, Tostes RC. Testosterone induces leucocyte migration by NADPH oxidase-driven ROS- and COX2- dependent mechanisms. Clin Sci (Lond) 129: 39–48, 2015.
33. Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR, Lopes LR, Avellar MC, Carvalho MH, Fortes ZB, Touyz RM, Tostes RC. Testosterone induces vascular smooth muscle cell migration by NADPH oxidase and c-Src-dependent pathways. Hypertension 59: 1263–1271, 2012.
34. Chinnathambi V, Blesson CS, Vincent KL, Saade GR, Hankins GD, Yallampalli C, Sathishkumar K. Elevated testosterone levels during rat pregnancy cause hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in uterine arteries. Hypertension 64: 405–414, 2014.
35. Chinnathambi V, More AS, Hankins GD, Yallampalli C, Sathishkumar K. Gestational exposure to elevated testosterone levels induces hypertension via heightened vascular angiotensin II type 1 receptor signaling in rats. Biol Reprod 91: 6, 2014.
36. Chinnathambi V, Yallampalli C, Sathishkumar K. Prenatal testosterone induces sex-specific dysfunction in endothelium-dependent relaxation pathways in adult male and female rats. Biol Reprod 89: 97, 2013.
37. Cho MH, Jung KJ, Jang HS, Kim JI, Park KM. Orchiectomy attenuates kidney fibrosis after ureteral obstruction by reduction of oxidative stress in mice. Am J Nephrol 35: 7–16, 2012.
38. Christakou CD, Diamanti-Kandarakis E. Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome. Womens Health 4: 583–594, 2008.
39. Clempus RE, Sorescu D, Dikalova AE, Pounkova L, Jo P, Sorescu GP, Schmidt HH, Lassegue B, Griendling KK. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 27: 42–48, 2007.
40. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, Melani C, Balzi D, Sforza A, Forti G, Mannucci E, Maggi M. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 7: 1557–1564, 2010.
41. Costa TJ, Ceravolo GS, dos Santos RA, de Oliveira MA, Araujo PX, Giaquinto LR, Tostes RC, Akamine EH, Fortes ZB, Dantas AP, Carvalho MH. Association of testosterone with estrogen abolishes the beneficial effects of estrogen treatment by increasing ROS generation in aorta endothelial cells. Am J Physiol Heart Circ Physiol 308: H723–H732, 2015.
42. Cunningham RL, Singh M, O’Bryant SE, Hall JR, Barber RC. Oxidative stress, testosterone, and cognition among Caucasian and Mexican- American men with and without Alzheimer’s disease. J Alzheimers Dis 40: 563–573, 2014.
43. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 17: 495–500, 2011.
44. de Souza-Junior TP, Yamada AK, Simao R, Polotow TG, Curi R, Pope Z, Willardson JM, Barros MP. Supra-physiological doses of testosterone affect membrane oxidation of human neutrophils monitored by the fluorescent probe C(1)(1)-BODIPY(5)(8)(1)/(5)(9)(1). Eur J Appl Physiol 113: 1241–1248, 2013.
45. Dikalov SI, Ungvari Z. Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol 305: H1417–H1427, 2013.
46. Dobrzycki S, Serwatka W, Nadlewski S, Korecki J, Jackowski R, Paruk J, Ladny JR, Hirnle T. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest 50: 162–169, 2003.
47. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47–95, 2002.
48. Edwards EA, Hamilton JB, Duntley SQ. Testosterone propionate as a therapeutic agent in patients with organic disease of the peripheral vessels—preliminary report. N Engl J Med 220: 865–865, 1939.
49. ElBaradie K, Wang Y, Boyan BD, Schwartz Z. Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes. J Steroid Biochem Mol Biol 132: 15–23, 2012.
50. Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NM, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol (Oxf) 209: 136–147, 2013.
51. Elnakish MT, Hassanain HH, Janssen PM, Angelos MG, Khan M. Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol 231: 290–300, 2013.
52. Ely D, Caplea A, Dunphy G, Daneshvar H, Turner M, Milsted A, Takiyyudin M. Spontaneously hypertensive rat Y chromosome increases indexes of sympathetic nervous system activity. Hypertension 29: 613–618, 1997.
53. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21: 890–894, 2000.
54. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 102: 1906–1911, 2000.
55. Fanaei H, Karimian SM, Sadeghipour HR, Hassanzade G, Kasaeian A, Attari F, Khayat S, Ramezani V, Javadimehr M. Testosterone enhances functional recovery after stroke through promotion of antioxidant defenses, BDNF levels and neurogenesis in male rats. Brain Res 1558: 74–83, 2014.
56. Fanton L, Belhani D, Vaillant F, Tabib A, Gomez L, Descotes J, Dehina L, Bui-Xuan B, Malicier D, Timour Q. Heart lesions associated with anabolic steroid abuse: comparison of post-mortem findings in athletes and norethandrolone-induced lesions in rabbits. Exp Toxicol Pathol 61: 317–323, 2009.
57. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164: 894–912, 2011.
58. Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95: 2560–2575, 2010.
59. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, Fraumeni JF Jr, Hoover RN. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 9: e85805, 2014.
60. Fisher M, Appleby M, Rittoo D, Cotter L. Myocardial infarction with extensive intracoronary thrombus induced by anabolic steroids. Br J Clin Pract 50: 222–223, 1996.
61. Food and Drug Administration. Adding general warning to testosterone products about potential for venous blood clots. http://www.fda.gov/Drugs/DrugSafety/ucm401746.htm. [06/19/2014, 2014].
62. Food and Drug Administration. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM383909.pdf.
63. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Front Neuroendocrinol 29: 169–181, 2008.
64. Fortepiani LA, Zhang H, Racusen L, Roberts LJ, 2nd, Reckelhoff JF. Characterization of an animal model of postmenopausal hypertension in spontaneously hypertensive rats. Hypertension 41: 640–645, 2003.
65. Frankenfeld SP, Oliveira LP, Ortenzi VH, Rego-Monteiro IC, Chaves EA, Ferreira AC, Leitao AC, Carvalho DP, Fortunato RS. The anabolic androgenic steroid nandrolone decanoate disrupts redox homeostasis in liver, heart and kidney of male Wistar rats. PLoS One 9: e102699, 2014.
66. Fu Y, Lu Y, Liu EY, Zhu X, Mahajan GJ, Lu D, Roman RJ, Liu R. Testosterone enhances tubuloglomerular feedback by increasing superoxide production in the macula densa. Am J Physiol Regul Integr Comp Physiol 304: R726–R733, 2013.
67. Garrido P, Salehzadeh F, Duque-Guimaraes DE, Al-Khalili L. Negative regulation of glucose metabolism in human myotubes by supraphysiological doses of 17-estradiol or testosterone. Metabolism 63: 1178–1187, 2014.
68. Germanakis I, Tsarouhas K, Fragkiadaki P, Tsitsimpikou C, Goutzourelas N, Champsas MC, Stagos D, Rentoukas E, Tsatsakis AM. Oxidative stress and myocardial dysfunction in young rabbits after short-term anabolic steroids administration. Food Chem Toxicol 61: 101–105, 2013.
69. Giorgio M. Oxidative stress and the unfulfilled promises of antioxidant agents. Ecancermedicalscience 9: 556, 2015.
70. Goldstein DR, Dobbs T, Krull B, Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteriograms. South Med J 91: 780–784, 1998.
71. Gonzales RJ, Ansar S, Duckles SP, Krause DN. Androgenic/estrogenic balance in the male rat cerebral circulation: metabolic enzymes and sex steroid receptors. J Cereb Blood Flow Metab 27: 1841–1852, 2007.
72. Gonzales RJ, Duckles SP, Krause DN. Dihydrotestosterone stimulates cerebrovascular inflammation through NF- B, modulating contractile function. J Cereb Blood Flow Metab 29: 244–253, 2009.
73. Gonzalez F, Nair KS, Daniels JK, Basal E, Schimke JM, Blair HE. Hyperandrogenism sensitizes leukocytes to hyperglycemia to promote oxidative stress in lean reproductive-age women. J Clin Endocrinol Metab 97: 2836–2843, 2012.
74. Green DR. Means to an end: apoptosis and other cell death mechanisms. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2011, p. xii, 220 p.
75. Grimm A, Schmitt K, Lang UE, Mensah-Nyagan AG, Eckert A. Improvement of neuronal bioenergetics by neurosteroids: implications for age-related neurodegenerative disorders. Biochim Biophys Acta 1842: 2427–2438, 2014.
76. Grollman A, Harrison TR, Williams JR. The effect of various sterol derivatives on the blood pressure of the rat. J Pharmacol Exp Ther 69: 149–155, 1940.
77. Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol 220: R37–R55, 2014.
78. Gurer B, Kertmen H, Kasim E, Yilmaz ER, Kanat BH, Sargon MF, Arikok AT, Erguder BI, Sekerci Z. Neuroprotective effects of testosterone on ischemia/reperfusion injury of the rabbit spinal cord. Injury 46: 240–248, 2015.
79. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolona ER, Sideras K, Uraga MV, Erwin PJ, Montori VM. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 82: 29–39, 2007.
80. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 82: 3793–3796, 1997.
81. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol 2: 325–328, 1942.
82. Hanchang W, Semprasert N, Limjindaporn T, Yenchitsomanus PT, Kooptiwut S. Testosterone protects against glucotoxicity-induced apoptosis of pancreatic -cells (INS-1) and male mouse pancreatic islets. Endocrinology 154: 4058–4067, 2013.
83. Haring R, Baumeister SE, Volzke H, Dorr M, Kocher T, Nauck M, Wallaschofski H. Prospective inverse associations of sex hormone concentrations in men with biomarkers of inflammation and oxidative stress. J Androl 33: 944–950, 2012.
84. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 34: 513–554, 2004.
85. Hilali N, Vural M, Camuzcuoglu H, Camuzcuoglu A, Aksoy N. Increased prolidase activity and oxidative stress in PCOS. Clin Endocrinol (Oxf) 79: 105–110, 2013.
86. Holmes S, Abbassi B, Su C, Singh M, Cunningham RL. Oxidative stress defines the neuroprotective or neurotoxic properties of androgens in immortalized female rat dopaminergic neuronal cells. Endocrinology 154: 4281–4292, 2013.
87. Hu XR, Rui L, Zhu TJ, Xia H, Yang XH, Wang XH, Liu HF, Lu ZB, Jiang H. Low testosterone level in middle-aged male patients with coronary artery disease. Eur J Intern Med 22: E133–E136, 2011.
88. Hurley BF, Seals DR, Hagberg JM, Goldberg AC, Ostrove SM, Holloszy JO, Wiest WG, Goldberg AP. High-density-lipoprotein cholesterol in bodybuilders v powerlifters. Negative effects of androgen use. JAMA 252: 507–513, 1984.
89. Hwang TI, Liao TL, Lin JF, Lin YC, Lee SY, Lai YC, Kao SH. Low-dose testosterone treatment decreases oxidative damage in TM3 Leydig cells. Asian J Androl 13: 432–437, 2011.
90. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SAP, Yeap BB. Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 97: 179–189, 2012.
91. Ide H, Lu Y, Yu J, China T, Kumamoto T, Koseki T, Yamaguchi R, Muto S, Horie S. Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines. Prostate 72: 1407–1411, 2012.
92. Ikeda Y, Aihara K, Yoshida S, Sato T, Yagi S, Iwase T, Sumitomo Y, Ise T, Ishikawa K, Azuma H, Akaike M, Kato S, Matsumoto T. Androgen-androgen receptor system protects against angiotensin IIinduced vascular remodeling. Endocrinology 150: 2857–2864, 2009.
93. Jacob MH, Janner Dda R, Bello-Klein A, Llesuy SF, Ribeiro MF. Dehydroepiandrosterone modulates antioxidant enzymes and Akt signaling in healthy Wistar rat hearts. J Steroid Biochem Mol Biol 112: 138–144, 2008.
94. Javeshghani D, Sairam MR, Schiffrin EL, Touyz RM. Increased blood pressure, vascular inflammation, and endothelial dysfunction in androgen-deficient follitropin receptor knockout male mice. J Am Soc Hypertens 1: 353–361, 2007.
95. Ji H, Menini S, Mok K, Zheng W, Pesce C, Kim J, Mulroney S, Sandberg K. Gonadal steroid regulation of renal injury in renal wrap hypertension. Am J Physiol Renal Physiol 288: F513–F520, 2005.
96. Juliet PA, Hayashi T, Daigo S, Matsui-Hirai H, Miyazaki A, Fukatsu A, Funami J, Iguchi A, Ignarro LJ. Combined effect of testosterone and apocynin on nitric oxide and superoxide production in PMAdifferentiated THP-1 cells. Biochim Biophys Acta 1693: 185–191, 2004.
97. Kabakci G, Yildirir A, Can I, Unsal I, Erbas B. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology 92: 221–225, 1999.
98. Kang SM, Jang Y, Kim J, Chung N, Cho SY, Chae JS, Lee JH. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89: 862–864, 2002.
99. Khalil RA. Sex hormones as potential modulators of vascular function in hypertension. Hypertension 46: 249–254, 2005.
100. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 116: 2694–2701, 2007.
101. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res 31: 71–79, 2008.
102. Kim J, Kil IS, Seok YM, Yang ES, Kim DK, Lim DG, Park JW, Bonventre JV, Park KM. Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem 281: 20,349–20,356, 2006.
103. Klapcinska B, Jagsz S, Sadowska-Krepa E, Gorski J, Kempa K, Langfort J. Effects of castration and testosterone replacement on the antioxidant defense system in rat left ventricle. J Physiol Sci 58: 173–177, 2008.
104. Ko E, Choi H, Kim B, Kim M, Park KN, Bae IH, Sung YK, Lee TR, Shin DW, Bae YS. Testosterone stimulates Duox1 activity through GPRC6A in skin keratinocytes. J Biol Chem 289: 28,835–28,845, 2014.
105. Komukai K, Mochizuki S, Yoshimura M. Gender and the reninangiotensin- aldosterone system. Fundam Clin Pharmacol 24: 687–698, 2010.
106. Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 151: 628–638, 2010.
107. Kumar DG, Deepa P, Rathi MA, Meenakshi P, Gopalakrishnan VK. Modulatory effects of Crataeva nurvala bark against testosterone and N-methyl-N-nitrosourea-induced oxidative damage in prostate of male albino rats. Pharmacogn Mag 8: 285–291, 2012.
108. Lepore G, Gadau S, Peruffo A, Mura A, Mura E, Floris A, Balzano F, Zedda M, Farina V. Aromatase expression in cultured fetal sheep astrocytes after nitrosative/oxidative damage. Cell Tissue Res 344: 407–413, 2011.
109. Lerchbaum E, Pilz S, Boehm BO, Grammer TB, Obermayer-Pietsch B, Marz W. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol 77: 475–483, 2012.
110. Lesser MA. The treatment of angina pectoris with testosterone propionate. Preliminary report. N Engl J Med 226: 51–54, 1942.
111. Li L, Guo CY, Jia EZ, Zhu TB, Wang LS, Cao KJ, Ma WZ, Yang ZJ. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian J Androl 14: 875–878, 2012.
112. Lin H, Lu JP, Laflamme P, Qiao S, Shayegan B, Bryskin I, Monardo L, Wilson BC, Singh G, Pinthus JH. Inter-related in vitro effects of androgens, fatty acids and oxidative stress in prostate cancer: a mechanistic model supporting prevention strategies. Int J Oncol 37: 761–766, 2010.
113. Littleton-Kearney M, Hurn PD. Testosterone as a modulator of vascular behavior. Biol Res Nurs 5: 276–285, 2004.
114. Liu S, Navarro G, Mauvais-Jarvis F. Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One 5: e11302, 2010.
115. Lopes RA, Neves KB, Pestana CR, Queiroz AL, Zanotto CZ, Chignalia AZ, Valim YM, Silveira LR, Curti C, Tostes RC. Testosterone induces apoptosis in vascular smooth muscle cells via extrinsic apoptotic pathway with mitochondria-generated reactive oxygen species involvement. Am J Physiol Heart Circ Physiol 306: H1485–H1494, 2014.
116. Luchtefeld M, Drexler H, Schieffer B. 5-Lipoxygenase is involved in the angiotensin II-induced NAD(P)H-oxidase activation. Biochem Biophys Res Commun 308: 668–672, 2003.
117. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96: 1821–1825, 2010.
118. Mancini A, Leone E, Festa R, Grande G, Silvestrini A, de Marinis L, Pontecorvi A, Maira G, Littarru GP, Meucci E. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl 29: 622–629, 2008.
119. Maric-Bilkan C, Manigrasso MB. Sex differences in hypertension: contribution of the renin-angiotensin system. Gend Med 9: 287–291, 2012.
120. Marin DP, Bolin AP, dos Santos Rde C., Curi R., Otton R. Testosterone suppresses oxidative stress in human neutrophils. Cell Biochem Funct 28: 394–402, 2010.
121. Marrachelli VG, Miranda FJ, Centeno JM, Burguete MC, Castello- Ruiz M, Jover-Mengual T, Perez AM, Salom JB, Torregrosa G, Alborch E. Mechanisms involved in the relaxant action of testosterone in the renal artery from male normoglycemic and diabetic rabbits. Pharmacol Res 61: 149–156, 2010.
122. Marrachelli VG, Miranda FJ, Centeno JM, Salom JB, Torregrosa G, Jover-Mengual T, Perez AM, Moro MA, Alborch E. Role of NOsynthases and cyclooxygenases in the hyperreactivity of male rabbit carotid artery to testosterone under experimental diabetes. Pharmacol Res 61: 62–70, 2010.
123. Martinez-Revelles S, Avendano MS, Garcia-Redondo AB, Alvarez Y, Aguado A, Perez-Giron JV, Garcia-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM, Salaices M. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51–65, 2013.
124. Martorell A, Blanco-Rivero J, Aras-Lopez R, Sagredo A, Balfagon G, Ferrer M. Orchidectomy increases the formation of prostanoids and modulates their role in the acetylcholine-induced relaxation in the rat aorta. Cardiovasc Res 77: 590–599, 2008.
125. Ment J, Ludman PF. Coronary thrombus in a 23 year old anabolic steroid user. Heart 88: 342, 2002.
126. Meydan S, Kus I, Tas U, Ogeturk M, Sancakdar E, Dabak DO, Zararsiz I, Sarsilmaz M. Effects of testosterone on orchiectomyinduced oxidative damage in the rat hippocampus. J Chem Neuroanat 40: 281–285, 2010.
127. Militaru C, Donoiu I, Dracea O, Ionescu DD. Serum testosterone and short-term mortality in men with acute myocardial infarction. Cardiol J 17: 249–253, 2010.
128. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 8: 1–28, 1987.
129. Morakinyo AO, Adekunbi DA, Dada KA, Adegoke OA. Testosterone promotes glucose intolerance, lipid disorder and oxidative stress in type 1 diabetic rats. J Basic Clin Physiol Pharmacol 25: 1–8, 2013.
130. Morales A. The long and tortuous history of the discovery of testosterone and its clinical application. J Sex Med 10: 1178–1183, 2013.
131. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc 90: 224–251, 2015.
132. Mostafa T, Rashed L, Kotb K, Taymour M. Effect of testosterone and frequent low-dose sildenafil/tadalafil on cavernous tissue oxidative stress of aged diabetic rats. Andrologia 44: 411–415, 2012.
133. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169: 725–733, 2013.
134. New MI, Josso N. Disorders of gonadal differentiation and congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 17: 339–366, 1988.
135. Oettel M. The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften 91: 66–76, 2004.
136. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85: 269–272, 2000.
137. Osterlund KL, Handa RJ, Gonzales RJ. Dihydrotestosterone alters cyclooxygenase-2 levels in human coronary artery smooth muscle cells. Am J Physiol Endocrinol Metab 298: E838–E845, 2010.
138. Ota H, Akishita M, Akiyoshi T, Kahyo T, Setou M, Ogawa S, Iijima K, Eto M, Ouchi Y. Testosterone deficiency accelerates neuronal and vascular aging of SAMP8 mice: protective role of eNOS and SIRT1. PLoS One 7: e29598, 2012.
139. Page-Wilson G, Goulart AC, Rexrode KM. Interrelation between sex hormones and plasma sex hormone-binding globulin and hemoglobin A1c in healthy postmenopausal women. Metab Syndr Relat Disord 7: 249–254, 2009.
140. Pansarasa O, D’Antona G, Gualea MR, Marzani B, Pellegrino MA, Marzatico F. “Oxidative stress”: effects of mild endurance training and testosterone treatment on rat gastrocnemius muscle. Eur J Appl Physiol 87: 550–555, 2002.
141. Papalia MA, Davis SR. What is the rationale for androgen therapy for women? Treat Endocrinol 2: 77–84, 2003.
142. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 31 Suppl 2: S170–S180, 2008.
143. Patel SM, Ratcliffe SJ, Reilly MP, Weinstein R, Bhasin S, Blackman MR, Cauley JA, Sutton-Tyrrell K, Robbins J, Fried LP, Cappola AR. Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 94: 4776–4784, 2009.
144. Perez-Torres I, Roque P, El Hafidi M, Diaz-Diaz E, Banos G. Association of renal damage and oxidative stress in a rat model of metabolic syndrome. Influence of gender. Free Radic Res 43: 761–771, 2009.
145. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary-artery disease in men. Arterioscler Thromb 14: 701–706, 1994.
146. Pick E. Role of the Rho GTPase Rac in the activation of the phagocyte NADPH oxidase: outsourcing a key task. Small GTPases 5: e27952, 2014.
147. Pingili AK, Kara M, Khan NS, Estes AM, Lin Z, Li W, Gonzalez FJ, Malik KU. 6-Hydroxytestosterone, a cytochrome P450 1B1 metabolite of testosterone, contributes to angiotensin II-induced hypertension and its pathogenesis in male mice. Hypertension 65: 1279–1287, 2015.
148. Pinthus JH, Bryskin I, Trachtenberg J, Lu JP, Singh G, Fridman E, Wilson BC. Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy. Neoplasia 9: 68–80, 2007.
149. Pisoschi AM, Pop A. The role of antioxidants in the chemistry of oxidative stress: A review. Eur J Med Chem 97: 55–74, 2015.
150. Ponikowska B, Jankowska EA, Maj J, Wegrzynowska-Teodorczyk K, Biel B, Reczuch K, Borodulin-Nadzieja L, Banasiak W, Ponikowski P. Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. Int J Cardiol 143: 343–348, 2010.
151. Prasad S, Kalra N, Singh M, Shukla Y. Protective effects of lupeol and mango extract against androgen induced oxidative stress in Swiss albino mice. Asian J Androl 10: 313–318, 2008.
152. Puttabyatappa Y, Stallone JN, Ergul A, El-Remessy AB, Kumar S, Black S, Johnson M, Owen MP, White RE. Peroxynitrite mediates testosterone-induced vasodilation of microvascular resistance vessels. J Pharmacol Exp Ther 345: 7–14, 2013.
153. Puurunen J, Piltonen T, Morin-Papunen L, Perheentupa A, Jarvela I, Ruokonen A, Tapanainen JS. Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 96: 1827–1834, 2011.
154. Pye SR, Huhtaniemi IT, Finn JD, Lee DM, O’Neill TW, Tajar A, Bartfai G, Boonen S, Casanueva FF, Forti G, Giwercman A, Han TS, Kula K, Lean ME, Pendleton N, Punab M, Rutter MK, Vanderschueren D, Wu FCW, Grp ES. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 99: 1357–1366, 2014.
155. Quan A, Chakravarty S, Chen JK, Chen JC, Loleh S, Saini N, Harris RC, Capdevila J, Quigley R. Androgens augment proximal tubule transport. Am J Physiol Renal Physiol 287: F452–F459, 2004.
156. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368–1376, 2011.
157. Razmara A, Duckles SP, Krause DN, Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res 1176: 71–81, 2007.
158. Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension 37: 1199–1208, 2001.
159. Reckelhoff JF, Yanes LL, Iliescu R, Fortepiani LA, Granger JP. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. Am J Physiol Renal Physiol 289: F941–F948, 2005.
160. Rezvanfar MA, Shojaei Saadi HA, Gooshe M, Abdolghaffari AH, Baeeri M, Abdollahi M. Ovarian aging-like phenotype in the hyperandrogenism- induced murine model of polycystic ovary. Oxid Med Cell Longev 2014: 948951, 2014.
161. Riezzo I, De Carlo D, Neri M, Nieddu A, Turillazzi E, Fineschi V. Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exercise-induced cardiotoxicity. Mini Rev Med Chem 11: 409–424, 2011.
162. Ripple MO, Hagopian K, Oberley TD, Schatten H, Weindruch R. Androgen-induced oxidative stress in human LNCaP prostate cancer cells is associated with multiple mitochondrial modifications. Antioxid Redox Signal 1: 71–81, 1999.
163. Rosano GM, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, della Monica PL, Bonfigli B, Volpe M, Chierchia SL. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99: 1666–1670, 1999.
164. Rosano GMC, Sheiban I, Massaro R, Pagnotta P, Marazzi G, Vitale C, Mercuro G, Volterrani M, Aversa A, Fini M. Low testosterone levels are associated with coronary artery disease in male patients with angina. Intl J Impot Res 19: 176–182, 2007.
165. Roy AK, Tyagi RK, Song CS, Lavrovsky Y, Ahn SC, Oh TS, Chatterjee B. Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann NY Acad Sci 949: 44–57, 2001.
166. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 29: 102–105, 2008.
167. Saborido A, Naudi A, Portero-Otin M, Pamplona R, Megias A. Stanozolol treatment decreases the mitochondrial ROS generation and oxidative stress induced by acute exercise in rat skeletal muscle. J Appl Physiol (1985) 110: 661–669, 2011.
168. Sadowska-Krepa E, Klapcinska B, Jagsz S, Chalimoniuk M, Chrapusta SJ, Wanke A, Grieb P, Langfort J. Diverging oxidative damage and heat shock protein 72 responses to endurance training and chronic testosterone propionate treatment in three striated muscle types of adolescent male rats. J Physiol Pharmacol 64: 639–647, 2013.
169. Schmitz I, Kirchhoff S, Krammer PH. Regulation of death receptormediated apoptosis pathways. Int J Biochem Cell Biol 32: 1123–1136, 2000.
170. Sedeek M, Hebert RL, Kennedy CR, Burns KD, Touyz RM. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 18: 122–127, 2009.
171. Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, Sharma R, Parashara D, Savin VJ, Ambrose JA, Barua RS. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J 36: 2706–2715, 2015.
172. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular eventfree survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93: 1276–1284, 2008.
173. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97: 2050–2058, 2012.
174. Siddiqui IA, Raisuddin S, Shukla Y. Protective effects of black tea extract on testosterone induced oxidative damage in prostate. Cancer Lett 227: 125–132, 2005.
175. Singh H, Cheng J, Deng H, Kemp R, Ishizuka T, Nasjletti A, Schwartzman ML. Vascular cytochrome P450 4A expression and 20- hydroxyeicosatetraenoic acid synthesis contribute to endothelial dysfunction in androgen-induced hypertension. Hypertension 50: 123–129, 2007.
176. Skogastierna C, Hotzen M, Rane A, Ekstrom L. A supraphysiological dose of testosterone induces nitric oxide production and oxidative stress. Eur J Prev Cardiol 21: 1049–1054, 2013.
177. Song D, Arikawa E, Galipeau D, Battell M, McNeill JH. Androgens are necessary for the development of fructose-induced hypertension. Hypertension 43: 667–672, 2004.
178. Song J, Wadhwa L, Bejjani BA, O’Brien WE. Determination of 3-keto-4-ene steroids and their hydroxylated metabolites catalyzed by recombinant human cytochrome P450 1B1 enzyme using gas chromatography- mass spectrometry with trimethylsilyl derivatization. J Chromatogr B Analyt Technol Biomed Life Sci 791: 127–135, 2003.
179. Stanworth RD, Jones TH. Testosterone for the aging male; current evidence and recommended practice. Clin Interv Aging 3: 25–44, 2008.
180. Sullivan JC, Sasser JM, Pollock JS. Sexual dimorphism in oxidant status in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 292: R764–R768, 2007.
181. Sun XY, Donald SP, Phang JM. Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22: 1775–1780, 2001.
182. Svartberg J, Von Muhlen D, Mathiesen E, Joakimsen O, Bonaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Int Med 259: 576–582, 2006.
183. Tam NN, Gao Y, Leung YK, Ho SM. Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 163: 2513–2522, 2003.
184. Tam NN, Ghatak S, Ho SM. Sex hormone-induced alterations in the activities of antioxidant enzymes and lipid peroxidation status in the prostate of Noble rats. Prostate 55: 1–8, 2003.
185. Tang EH, Vanhoutte PM. Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions. Pharmacol Ther 122: 140–149, 2009.
186. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 5: 315–321, 2012.
187. Tothova L, Celec P, Ostatnikova D, Okuliarova M, Zeman M, Hodosy J. Effect of exogenous testosterone on oxidative status of the testes in adult male rats. Andrologia 45: 417–423, 2013.
188. Toufexis DJ, Wilson ME. Dihydrotestosterone differentially modulates the cortisol response of the hypothalamic-pituitary-adrenal axis in male and female rhesus macaques, and restores circadian secretion of cortisol in females. Brain Res 1429: 43–51, 2012.
189. Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 1: 91–106, 2003.
190. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34: 5–14, 2011.
191. Touyz RM, Wu XH, He G, Park JB, Chen X, Vacher J, Rajapurohitam V, Schiffrin EL. Role of c-Src in the regulation of vascular contraction and Ca2+signaling by angiotensin II in human vascular smooth muscle cells. J Hypertens 19: 441–449, 2001.
192. Trabado S, Lamothe S, Maione L, Bouvattier C, Sarfati J, Brailly- Tabard S, Young J. Congenital hypogonadotropic hypogonadism and Kallmann syndrome as models for studying hormonal regulation of human testicular endocrine functions. Ann Endocrinol (Paris) 75: 79–87, 2014.
193. Veeramani S, Yuan TC, Lin FF, Lin MF. Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. Oncogene 27: 5057–5068, 2008.
194. Victor VM, Rocha M, Banuls C, Rovira-Llopis S, Gomez M, Hernandez- Mijares A. Mitochondrial impairment and oxidative stress in leukocytes after testosterone administration to female-to-male transsexuals. J Sex Med 11: 454–461, 2014.
195. Vigen R, O’Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310: 1829–1836, 2013.
196. Vikan T, Johnsen SH, Schirmer H, Njolstad I, Svartberg J. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromso study. Eur J Epidemiol 24: 289–295, 2009.
197. Virdis A, Colucci R, Fornai M, Blandizzi C, Duranti E, Pinto S, Bernardini N, Segnani C, Antonioli L, Taddei S, Salvetti A, Del Tacca M. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitricoxide synthase and oxidative stress. J Pharmacol Exp Ther 312: 945–953, 2005.
198. Walker TC. Use of testosterone propionate and estrogenic substance in treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol 2: 560–568, 1942.
199. Webb CM, Adamson DL, de Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83: 437–439, A439, 1999.
200. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100: 1690–1696, 1999.
201. Yanar K, Atukeren P, Cebe T, Kunbaz A, Ozan T, Kansu AD, Durmaz S, Gulec V, Belce A, Aydin S, Cakatay U, Rizvi SI. Ameliorative effects of testosterone administration on renal redox homeostasis in naturally aged rats. Rejuvenation Res 18: 299–312, 2015.
202. Yanes LL, Romero DG, Moulana M, Lima R, Davis DD, Zhang H, Lockhart R, Racusen LC, Reckelhoff JF. Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome. Gend Med 8: 103–115, 2011.
203. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res 95: 173–182, 2012.
204. Zhang GL, Wang W, Kang YX, Xue Y, Yang H, Zhou CM, Shi GM. Chronic testosterone propionate supplement could activated the Nrf2- ARE pathway in the brain and ameliorated the behaviors of aged rats. Behav Brain Res 252: 388–395, 2013.
205. Zhang L, Lei D, Zhu GP, Hong L, Wu SZ. Physiological testosterone retards cardiomyocyte aging in Tfm mice via androgen receptor-independent pathway. Chin Med Sci J 28: 88–94, 2013.
206. Zhang L, Wu S, Ruan Y, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Mol Med Rep 4: 1183–1188, 2011.
207. Zuloaga KL, Gonzales RJ. Dihydrotestosterone attenuates hypoxia inducible factor-1and cyclooxygenase-2 in cerebral arteries during hypoxia or hypoxia with glucose deprivation. Am J Physiol Heart Circ Physiol 301: H1882–H1890, 2011.